Status:
ACTIVE_NOT_RECRUITING
Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Conditions:
Myeloma
Lymphoma
Eligibility:
All Genders
60+ years
Brief Summary
A prospective study in which hematological oncology patients who were vaccinated against RSV will undergo a blood test to assess their immune response to the vaccine. As part of the study, hematologic...
Detailed Description
participants 250 Single-center Research hypothesis approximately 60%-70% of the 250 hematological oncology patients who will participate in the study will achieve a positive serological response. This...
Eligibility Criteria
Inclusion
- Patients aged 60 years and older
- Patients diagnosed with multiple myeloma(MM) or lymphoma or CLL or myelodysplastic syndrome (MDS) or acute leukemia
Exclusion
- Patients who have been previously vaccinated against RSV
- Patients who have experienced a severe reaction to any vaccine in the past
Key Trial Info
Start Date :
January 20 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2027
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT06944119
Start Date
January 20 2025
End Date
March 1 2027
Last Update
July 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel